Rebastinib

DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.

Price Not Available 25 mg Rebastinib Supplier Page

Catalog Number	T2640
Alternative Name(s)	DCC2036 , DCC 2036 , DCC-2036
Research Area	Apoptosis\|\|\|Angiogenesis\|\|\|Tyrosine Kinase/Adaptors\|\|\|Cytoskeletal Signaling
Molecular Formula	C30H28FN7O3
CAS#	1020172-07-9
SMILES	CNC(=O)c1nccc(Oc2cc(F)c(NC(=O)Nc3cc(nn3c3cc4c(cc3)nccc4)C(C)(C)C)cc2)c1
Size	25 mg
Supplier Page	https://www.targetmol.com/compound/Rebastinib
Additional Information	https://www.targetmol.com/datasheet/T2640